Drug-eluting stents in peripheral vascular disease: eliminating restenosis.
Transcatheter endovascular therapy for peripheral atherosclerotic disease has become more popular. In general, good results have been reported in focal aortoiliac disease. However, the long-term patency of angioplasty in longer, more distal lesions has been less satisfactory. Stenting has not been shown to improve long-term patency compared to angioplasty alone. Drug-eluting stents have shown promise in preventing coronary restenosis, and preliminary results in peripheral arterial disease are encouraging. This review article will discuss the current status of endovascular therapy of aortoiliac and femoropopliteal atherosclerotic disease, the theoretic and experimental basis for the use of drug-eluting stents, and the preliminary results in human studies.
Ellozy
Sharif H
SH
Department of Surgery, Mount Sinai School of Medicine, One East 100th Street, New York, NY 10029, USA. sharif.ellozy@msnyuhealth.org
Carroccio
Alfio
A
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D001157:Arterial Occlusive Diseases / Q000517:prevention & control*; D023903:Coronary Restenosis / Q000517:prevention & control; D016503:Drug Delivery Systems; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D016491:Peripheral Vascular Diseases / Q000188:drug therapy*; D011474:Prosthesis Design; D012008:Recurrence; D020123:Sirolimus / Q000008:administration & dosage; D015607:Stents; D014654:Vascular Patency
D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D020123:Sirolimus